Law360, New York (March 09, 2009) -- As Merck & Co. prepares to join forces with Schering-Plough Co. in a $41.1 billion deal, the drugmaker stands ready to inherit a host of legal problems — including antitrust, employment, intellectual property and product liability suits — right along with an expanded arsenal of drugs and medical technology.
On Monday, Merck and Schering revealed the proposed union, which, if approved by regulators, would be helmed by Merck Chairman and CEO Richard Clark and operate under the Merck name....
